TABLE 3.
Plasma PK parameters after single-dose administration of narlaprevir (part 1) and narlaprevir with ritonavir (part 2) in patients with compensated cirrhosis and in healthy subjectsa
| Investigated regimen | Parameter | GMEAN |
P/H | 90% CI |
||
|---|---|---|---|---|---|---|
| Cirrhotic patients (n = 8) | Healthy subjects (n = 8) | Lower | Upper | |||
| NVR at 200 mg (part 1) | AUC0–∞ (ng · h/ml) | 4,701.8 | 1,917.1 | 2.45 | 1.56 | 3.85 |
| Cmax (ng/ml) | 563.1 | 364.8 | 1.54 | 1.05 | 2.27 | |
| NVR at 100 mg + RTV at 100 mg (part 2) | AUC0–∞ (ng · h/ml) | 15,213.1 | 14,257.2 | 1.07 | 0.72 | 1.58 |
| Cmax (ng/ml) | 1,225.7 | 1,178.9 | 1.04 | 0.67 | 1.63 | |
a
Cmax and AUC0–∞ are presented as arithmetic means. P/H, patient/healthy subject ratio; NVR, narlaprevir; RTV, ritonavir.